AI Science Tracker

Graph neural networks trained on a 2,352-compound screen find three selective senolytic compounds

Massachusetts Institute of Technology · 4 May 2023 · medicine

Discovery

Graph neural networks trained on a 2,352-compound screen find three selective senolytic compounds

Source check: Needs source check. Not independent scientific confirmation.

Finding: Wong et al. screened 2,352 compounds for senolytic activity in etoposide-induced senescence, trained graph neural networks on the results and scored more than 800,000 molecules. Three drug-like hits selectively killed senescent cells across senescence models with selectivity comparable to ABT-737; docking and TR-FRET suggest partial Bcl-2 inhibition. One compound, BRD-K56819078, reduced senescent-cell burden and senescence-associated gene expression in kidneys of aged mice. Evidence is from the abstract only; effect sizes, mouse numbers and the absence of efficacy or safety data in humans are not assessed here.

Technology: Chemprop message-passing graph neural networks

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

AI contribution
Graph neural networks trained on the experimental screen ranked more than 800,000 molecules, enriching for structurally diverse senolytic hits.
Test and result
Screening hits were tested in cell models of senescence, mechanism was probed by docking and TR-FRET, and one compound was tested in aged mice (per abstract).
Limitation / still unknown
Independent replication, human data and full Methods were not assessed.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://europepmc.org/article/MED/37142829

Needs source check · editorial details

The source has not been fully checked or contains conflicting information. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 17 Nov 2026. Review scope: abstract and bibliographic metadata (Europe PMC) only; Methods and full text not assessed.

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open in the full catalog for filters, charts and related discoveries. Browse medicine discoveries.

Related catalog entries

Links use documented relationships where available, plus shared catalog context. A shared topic or model family does not establish a scientific dependency.